ワルダイヤ輪初発非ホジキンリンパ腫（Ｓｔａｇｅ　ＩＥ，ＩＩＥ）の治療　　成人病合併例に対する局所および隣接リンパ節領域照射と短期減量化学療法の有用性

DOI 参考文献20件 オープンアクセス

書誌事項

タイトル別名
  • Local and reginonal irradiation and brief reduced-dose chemotherapy for non-Hodgkin's lymphoma (stage IE,IIE)of Waldeyer's ring with adult diseases.
  • 成人病合併例に対する局所および隣接リンパ節領域照射と短期減量化学療法の有用性

この論文をさがす

説明

Purpose: Usually, the middle-aged patients with non-Hodgkin's lymphoma and concomitant other adult diseases can not be tolerable for intensive chemotherapy. Then we introduced a new regimen composed of radiation for local and sorrounding lymph node areas, and brief reduced-dose chemotherapy into treatment for such patients.<br>Subjects and Methods: Thirth-eight patients with Stage IE or Stage IIE non-Hodgkin's lymphoma of the Waldeyer's ring were a core of this study. Histopathologically they were diagnosed as diffuse intermediate grade. In addi-tion, they suffered from other adult diseases such as cardiovascular diseases, cereblovascular disorders, diabetus melitus, chronic liver diseases, etc. They were treated by the combined modality composed of reduced-dose chemo-therapy (70%-ACOP: 2 cycles or 70%-MACOP-B: 8 weeks) and regional lymph node irradiation (30Gy) puls boost irradiation (10Gy) to inolved area (total 40Gy).<br>Results: No relapses were observed in the radiation field, the 5-year disease-free survival rate and cause-specific survival rate for all patients were 85.7% and 91.4%, respectively. There were no differences of the 5-year disease-free survival rate between stage IE and IIE, among the pathological subtypes, among the complications and etc.<br>Conclusion: The regimen composed of regional lymph node irradiation (30Gy) puls boost irradiation (10Gy) to involved area (total 40Gy) and reduced-dose chemotherapy (70%-dose ACOP, 70%-dose MACOP-B) is a safe and useful approach to treatment for diffuse intermediate grade of B cell lymphoma in middle-aged patients having other adult diseases.

収録刊行物

  • 頭頸部腫瘍

    頭頸部腫瘍 23 (1), 28-33, 1997

    日本頭頸部癌学会

参考文献 (20)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ